SALT LAKE CITY, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics Inc. (MYGN) (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a strategic partnership with jscreen™, ...

Prospective Clinical Study Showed the myRisk Test Identified 70 Percent More Deleterious Mutations than BRCA Testing Alone with 42 Percent of These in Women Over Age 45 Myriad Genetics, Inc. (NASDAQ: ...

Myriad Genetics pioneered and was the market leader in BRCA testing for over ten years. Analysts write that CEO Paul Diaz has successfully addressed Myriad's operational and innovation challenges.

Shares in diagnostic company Myriad Genetics (MYGN) were trading up sharply on Wednesday after a surprise announcement from the Centers for Medicare and Medicaid Services (CMS) announced that it was ...

SALT LAKE CITY, June 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN) (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with GSK aimed at ...

SALT LAKE CITY, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Japan’s Ministry of Health, Labour and ...

Oct 15 (Reuters) - Quest Diagnostics Inc on Tuesday became the largest U.S. company to start offering gene-based tests for inherited forms of breast cancer since the U.S. Supreme Court ended Myriad ...

Myriad Genetics, Inc. (NASDAQ: MYGN) today announced new clinical studies on its myChoice HRD companion diagnostic test at the 2015 American Society of Clinical Oncology annual meeting being held in ...

It may be an understatement to say that it's been an important year for Myriad Genetics A court order essentially invalidated patent protection for its best selling BRACAnalysis test last summer. That ...

Piper Sandler initiated coverage on Myriad Genetics Inc (NASDAQ:MYGN), noting that many investors know the company as one of the earliest pioneers of genetic testing. Myriad develops and offers ...